United Therapeutics Corp
NASDAQ:UTHR
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
210.76
410
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
United Therapeutics Corp
United Therapeutics Corp
Operating Income
United Therapeutics Corp
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
United Therapeutics Corp
NASDAQ:UTHR
|
Operating Income
$1.3B
|
CAGR 3-Years
32%
|
CAGR 5-Years
14%
|
CAGR 10-Years
15%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Income
$15.4B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Income
$10.9B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
20%
|
CAGR 10-Years
-1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Income
$6.2B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Income
$4.3B
|
CAGR 3-Years
17%
|
CAGR 5-Years
40%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Income
$4.2B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
13%
|
CAGR 10-Years
18%
|
|
United Therapeutics Corp
Glance View
United Therapeutics Corp. is a biotechnology company that has carved out a vital niche in the biopharma landscape by focusing on innovative treatments for rare diseases, particularly pulmonary arterial hypertension (PAH). Founded in 1996 and headquartered in Silver Spring, Maryland, the company has developed an impressive portfolio of therapies that address unmet medical needs. At the heart of its mission is the determination to extend the lives of patients suffering from chronic, life-threatening conditions. This commitment to innovation has led to the successful launch of multiple FDA-approved products, such as Remodulin and Tyvaso, which offer significant improvements in both the quality and length of life for those contending with PAH. As an investor, what sets United Therapeutics apart is not only its robust product pipeline but also its strategic approach to growth, which includes collaborations with renowned institutions and a commitment to research and development. The company's pipeline boasts promising candidates that target various indications beyond PAH, including efforts to tackle organ transplantation challenges, which aligns with its overarching purpose of saving lives. Furthermore, United Therapeutics stands out with its business model focused on sustainable growth through both commercial success and a vision driven by social responsibility. For investors, this dual commitment to profitability and patient care positions United Therapeutics as a company with long-term potential, making it an intriguing candidate in the biotech investment landscape.
See Also
What is United Therapeutics Corp's Operating Income?
Operating Income
1.3B
USD
Based on the financial report for Sep 30, 2024, United Therapeutics Corp's Operating Income amounts to 1.3B USD.
What is United Therapeutics Corp's Operating Income growth rate?
Operating Income CAGR 10Y
15%
Over the last year, the Operating Income growth was 21%. The average annual Operating Income growth rates for United Therapeutics Corp have been 32% over the past three years , 14% over the past five years , and 15% over the past ten years .
You don't have any saved screeners yet
